✨ Free AI Report
Crinetics Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Crinetics Pharmaceuticals, Inc.
Company Research

Crinetics Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Crinetics Pharmaceuticals, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Commercial-stage endocrine specialist with first-to-market acromegaly therapy and promising late-stage pipeline backed by strong balance sheet. PALSONIFY is the first FDA-approved oral treatment for acromegaly, representing significant commercial validation. In December 2025, atumelnant entered Phase 3 clinical trials for congenital adrenal hyperplasia, demonstrating strong pipeline momentum. Recent $350M financing.

What is Crinetics Pharmaceuticals, Inc.'s industry? Crinetics Pharmaceuticals, Inc. (crinetics.com) operates in Biopharmaceutical - Specialty Endocrinology. AskCyborg classifies Crinetics Pharmaceuticals, Inc. under Biopharmaceutical - Specialty Endocrinology in its company registry.

Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases. The company's lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment...

7/ 10Strong

Cyborg Score thesis

Commercial-stage endocrine specialist with first-to-market acromegaly therapy and promising late-stage pipeline backed by strong...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Specialty Endocrinology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Crinetics Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Crinetics Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Crinetics Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Crinetics Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Crinetics Pharmaceuticals, Inc. Overview

Pro stress-test →

Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases. The company's lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

Strategic Profile

Pro stress-test →

Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties. The company raised approximately $350 million in gross proceeds from a January 2026 public offering to fund PALSONIFY launch and an extensive pipeline of 10+ programs in clinical development.

Competitive Landscape

Pro stress-test →

Crinetics is a clinical-stage to early-commercial pharmaceutical company in the rare endocrine diseases and endocrine-related tumors space, with paltusotine in Phase 3 development. Primary competitors are established endocrine specialists and diversified pharma companies with competing acromegaly and CAH treatments, though PALSONIFY's first-to-market oral status represents a significant competitive advantage.

Industry Context

Crinetics Pharmaceuticals, Inc. operates in Biopharmaceutical - Specialty Endocrinology.

Key facts

Founded: 2008 · Headquarters: San Diego, US · Revenue: $1.0M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Crinetics Pharmaceuticals, Inc..

  • PALSONIFY is approved for acromegaly with inadequate surgical response; paltusotine is also in clinical development for carcinoid syndrome
  • Phase 3 atumelnant trial for congenital adrenal hyperplasia initiated December 2025 following positive Phase 2 data
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Fourth quarter and full year 2025 financial results scheduled for reporting February 26, 2026
  • January 2026Completed $350 million public offering at $45.95 per share
  • +2 moreTrack every material event for Crinetics Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Crinetics Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SomavertPegvisomant for acromegaly→SandostatinOctreotide for acromegaly and neuroendocrine tumors→SomatulineLanreotide for acromegaly and neuroendocrine tumors→

Compare Crinetics Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Crinetics Pharmaceuticals, Inc. operates in Biopharmaceutical - Specialty Endocrinology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Specialty Endocrinology research →
NEW · MCP server

Ask your AI assistant about Crinetics Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Crinetics Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Crinetics Pharmaceuticals, Inc. do this quarter?”
“Is Crinetics Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Crinetics Pharmaceuticals, Inc. do?+
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases. The company's lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment...
What is Crinetics Pharmaceuticals, Inc.'s Cyborg Score?+
Crinetics Pharmaceuticals, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Crinetics Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Somavert, Sandostatin, Somatuline. The full competitive landscape is in the AskCyborg report.
How can I get the full Crinetics Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Crinetics Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Crinetics Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.